Carbone Claudia, Rende Pierandrea, Comberiati Pasquale, Carnovale Domenico, Mammì Maria, De Sarro Giovambattista
Department of Science of Health, School of Medicine, University of Catanzaro and Pharmacovigilance's Centre Calabria Region, University Hospital Mater Domini, Catanzaro, Italy.
J Pharmacol Pharmacother. 2013 Dec;4(Suppl 1):S99-S103. doi: 10.4103/0976-500X.120967.
Ketoprofen is a non-steroidal anti-inflammatory drug (NSAID), which acts by blocking cyclooxygenase (COX 1 and 2), an enzyme involved in the production of prostaglandins, messengers in the development of inflammation. All NSAIDs reduce signs of inflammation by blocking this enzyme and therefore prostaglandin production. In Calabria, 3.69% of adverse drug reactions (ADRs) reported in the National Network of Pharmacovigilance concerns the use of ketoprofen; only in one case in which the patient was under the age of 12 years, hospitalization was required for severe episode of pancreatitis. In Italy, Ketoprofen is the 6(th) drug for ADRs incidence (560 ADRs in the year 2012, of which, 31% are severe). Despite the high rate of spontaneous reporting, it must be considered that ketoprofen is one of the most used NSAIDs; therefore, as it happens for other commonly used drugs (eg, amoxicillin), the total number of ADRs should be related to the therapeutic use. However, it remains the problem of fragile patients (eg, children) and the safety of the drug in different ages. This paper presents a retrospective study on 2012 ADRs reviewing literature on the safety of ketoprofen in the elderly, children, and during pregnancy.
酮洛芬是一种非甾体抗炎药(NSAID),其作用机制是阻断环氧化酶(COX 1和2),该酶参与前列腺素的生成,而前列腺素是炎症发展过程中的信使。所有非甾体抗炎药都通过阻断这种酶从而减少前列腺素的生成来减轻炎症迹象。在卡拉布里亚,国家药物警戒网络报告的药物不良反应(ADR)中有3.69%与酮洛芬的使用有关;只有1例12岁以下患者因严重胰腺炎发作需要住院治疗。在意大利,酮洛芬是药物不良反应发生率排名第6的药物(2012年有560例药物不良反应,其中31%为严重不良反应)。尽管自发报告率很高,但必须考虑到酮洛芬是使用最广泛的非甾体抗炎药之一;因此,与其他常用药物(如阿莫西林)一样,药物不良反应的总数应与治疗用途相关。然而,脆弱患者(如儿童)的问题以及该药物在不同年龄段的安全性仍然存在。本文对2012年的药物不良反应进行了回顾性研究,并综述了酮洛芬在老年人、儿童和孕期安全性方面的文献。